Successful reduction of immunosuppression in older renal transplant recipients who exhibit donor-specific regulation

Transplantation

Volumn 88, Issue 4, 2009, Pages 533-541

  Jankowska Gan, Ewa ^a   Sollinger, Hans W ^a   Pirsch, John D ^a   Cai, Junchao ^b   Pascual, Julio ^c   Haynes, Lynn D ^a   Munoz Del Rio, Alenjandro ^a   Burlingham, William J ^a,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d G4/702 CSC ^*  (United States)

Author keywords

Donor specific antibody; Donor specific regulation; Steroid withdrawal; Trans vivo delayed type hypersensitivity; Transplant Patient

Indexed keywords

CREATININE; CYCLOSPORIN; HLA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ACUTE GRAFT REJECTION; ANIMAL EXPERIMENT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DELAYED HYPERSENSITIVITY; DRUG WITHDRAWAL; FOLLOW UP; GROUPS BY AGE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; STEROID THERAPY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; AGING; ANIMALS; CALCINEURIN; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MICE; MICE, SCID; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; T-LYMPHOCYTES, REGULATORY; TISSUE DONORS;

EID: 70349141830     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b0f92f     Document Type: Article

References (42)

1. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
2. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation-How much of the promise has been realized? Nat Med 2005; 11: 605.
3. Augustine JJ, Hricik DE. Minimization of immunosuppression in kidney transplantation. Curr Opin Nephrol Hypertens 2007; 16: 535.
4. Keunecke C, Rothenpieler U, Zanker B, et al. Mycophenolate mofetil monotherapy: An example of a safe nephrotoxicity/atherogenicity-free immunosuppressive maintenance regimen in a selected group of kidney-transplanted patients. Transplant Proc 2000; 32(1A suppl): 6S.
5. Veenstra DL, Best JH, Hornberger J, et al. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33: 829.
6. Vincenti F, Schena FP, Paraskevas S, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307.
7. Roelen DL, Van Bree SP, Van Beelen E, et al. Cytotoxic T lymphocytes against HLA-B antigens are less naive than cytotoxic T lymphocytes against HLA-A antigens. Transplantation 1994; 57: 446.
8. Kusaka S, Grailer AP, Fechner JH Jr, et al. Clonotype analysis of human alloreactive T cells: A novel approach to studying peripheral tolerance in transplant recipients. J Immunol 2000; 164: 2240.
9. Yamada A, Chandraker A, Laufer TM, et al. Recipient MHC class II expression is required to achieve long-term survival of murine cardiac allografts after costimulatory blockade. J Immunol 2001; 167: 5522.
10. Carrodeguas L, Orosz CG, Waldman WJ, et al. Trans vivo analysis of human delayed-type hypersensitivity reactivity. Hum Immunol 1999; 60: 640.
11. VanBuskirk AM, Burlingham WJ, Jankowska-Gan E, et al. Human al-lograft acceptance is associated with immune regulation. J Clin Invest 2000; 106: 145.
12. Cai J, Lee J, Jankowska-Gan E, et al. Minor H antigen HA-1-specific regulator and effector CD8- T Cells, and HA-1 microchimerism, in allograft tolerance. J Exp Med 2004; 199: 1017.
13. Xu Q, Lee J, Jankowska-Gan E, et al. Human CD4-CD25 low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance. J Immunol 2007; 178: 3983.
14. Torrealba JR, Katayama M, Fechner JH Jr, et al. Metastable tolerance to rhesus monkey renal transplants is correlated with allograft TGF-beta 1-CD4- T regulatory cell infiltrates. J Immunol 2004; 172: 5753.
15. Geissler F, Jankowska-Gan E, DeVito-Haynes LD, et al. Human liver allograft acceptance and the 'tolerance assay': In vitro anti-donor T cell assays show hyporeactivity to donor cells but, unlike DTH, fail to detect linked suppression. Transplantation 2001; 72: 571.
16. Derks RA, Jankowska-Gan E, Xu Q, et al. Dendritic cell type determines the mechanism of bystander suppression by adaptive T regulatory cells specific for the minor antigen HA-1. J Immunol 2007; 179: 3443.
17. Jankowska-Gan E, Rhein T, Haynes L, et al. Human liver allograft acceptance and the 'tolerance assay' II. Donor HLA-A, -B but not DR antigens are able to trigger regulation of DTH. Hum Immunol 2002; 63: 862.
18. Clubotariu R, Zhuoru L, Colovai A, et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998; 101: 1.
19. Poggio ED, Clemente M, Riley J, et al. Alloreactivity in renal transplant recipients with and without chronic allograft nephropathy. J Am Soc Nephrol 2004; 15: 1952.
20. Gould DS, Auchincloss H Jr. Direct and indirect recognition: The role of MHC antigens in graft rejection. Immunol Today 1999; 20: 77.
21. Jiang S, Camara N, Lombardi G, et al. Induction of allopeptide-specific human CD4-CD25-regulatory T cells ex vivo. Blood 2003; 102: 2180.
22. Ismail N, Hakim RM, Helderman JH. Renal replacement therapies in the elderly. II. Renal transplantation. Am J Kidney Dis 1994; 23: 1.
23. Matas A. Chronic rejection in renal transplant recipients-Risk factors and correlates. Clin Transplant 1994; 8: 332.
24. Rodriguez DS, Jankowska-Gan E, Haynes LD, et al. Immune regulation and graft survival in kidney transplant recipients are both enhanced by human leukocyte antigen matching. Am J Transplant 2004; 4: 537.
25. Warnecke G, Chapman SJ, Bushell A, et al. Dependency of the trans vivo delayed type hypersensitivity response on the action of regulatory T cells: Implications for monitoring transplant tolerance. Transplantation 2007; 84: 392.
26. VanBuskirk AM, Wakely ME, Sirak JH, et al. Patterns of allosensitization in allograft recipients: Long-term cardiac allograft acceptance is associated with active alloantibody production in conjunction with active inhibition of alloreactive delayed-type hypersensitivity. Transplantation 1998; 65: 1115.
27. Burlingham WJ, Jankowska-Gan E, VanBuskirk AM, et al. Loss of tolerance to a maternal kidney transplant is selective for HLA class II: Evidence from trans-vivo DTH and alloantibody analysis. Hum Immu-nol 2000; 61: 1395.
28. Lafferty KJ, Babcock SK, Gill RG. Prevention of rejection by treatment of the graft: An overview. Prog Clin Biol Res 1986; 224: 87.
29. Pelletier RP, Hennessy PK, Adams PW, et al. High incidence of donor-reactive delayed-type hypersensitivity reactivity in transplant patients. Am J Transplant 2002; 2: 926.
30. Knechtle SJ, Pascual J, Bloom DD, et al. Early and limited use of tacroli-mus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: Clinical results and immune monitoring. Am J Transplant 2009; 9: 1087.
31. Lim HW, Hillsamer P, Kim CH. Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. J Clin Invest 2004; 114: 1640.
32. Ayoub G, Terasaki P. HLA-DR matching in multicenter, single-typing laboratory data. Transplantation 1982; 33: 515.
33. Opelz G. Cadaver kidney graft outcome in relation to ischemia time and HLA match. Collaborative Transplant Study. Transplant Proc 1998; 30: 4294.
34. Pirsch JD, D'Alessandro AM, Sollinger HW, et al. The effect of donor age, recipient age, and HLA match on immunologic graft survival in cadaver renal transplant recipients. Transplantation 1992; 53: 55.
35. Molitor-Dart ML, Andrassy J, Kwun J, et al. Developmental exposure to noninherited maternal antigens induces CD4- T regulatory cells: Relevance to mechanism of heart allograft tolerance. J Immunol 2007; 179: 6749.
36. Pelletier RP, Bickerstaff AA, Adams PW, et al. Evaluation of immune regulation in transplant patients using the trans vivo delayed type hypersensitivity assay. Hum Immunol 2007; 68: 514.
37. Burlingham WJ, Jankowska-Gan E. Mouse strain and injection site are crucial for detecting linked suppression in transplant recipients by trans-vivo DTH assay. Am J Transplant 2007; 7: 466.
38. Jankowska-Gan ERD, Knechtle SJ, Burlingham WJ, et al. Histopatho-logic evidence for linked suppression detected by the Trans-Vivo DTH: Footpad differs from ear [abstract]. Am J Transplant 2007; 7(suppl 2): 579.
39. Burlingham WJ, Love RB, Jankowska-Gan E, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bron-chiolitis in human lung transplants. J Clin Invest 2007; 117: 3498.
40. Bobadilla JL, Love RB, Jankowska-Gan E, et al. TH-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med 2008; 177: 660.
41. Marteau F, Gonzalez NS, Communi D, et al. Thrombospondin-1 and indoleamine 2,3-dioxygenase are major targets of extracellular ATP in human dendritic cells. Blood 2005; 106: 3860.
42. Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil-A prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999; 68: 1865.